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Abstract
Juvenile idiopathic arthritis is the most common chronic rheumatic condition during childhood. Temporomandibular
joint arthritis is frequently asymptomatic. When it takes place during childhood, it may affect condylar growth;
therefore, these children are at risk of unfavorable long-term outcomes from the associated joint damage. The
etiology is not completely understood, but it is considered as multifactorial with both genetic and environmental
factors involved.
The standardized examination and imaging protocols serve important purpose to diagnose temporomandibular
joint (TMJ) arthritis not only to establish an early interventional strategy but also to assess craniofacial growth and
the progression of signs and symptoms in those patients. Although the treatment of juvenile idiopathic arthritis
(JIA) has changed dramatically over the last decades due to new therapeutic options, TMJ arthritis still can develop
during the course of the disease. In clinical experience, TMJs appear to respond less well to the standard of care used
to treat other joints. More individualized approach to the patient’s treatment serves as the main goal of personalized
medicine. It could be achieved by adopting new methods of medical imaging such as conebeam computer
tomography as well as developing reliable biomarkers which may assist with predicting disease type, course, or
severity and predicting response to medication.
This article provides an overview of current information on orofacial complications in JIA and its management.
Based on information provided in this review, more precise diagnosis, proper tools for recognizing people at risk,
and more efficient treatment approaches could be implemented. This may lead to more personalized treatment
management strategies of TMJ complications of JIA patients.
Keywords: Biomarkers, Craniofacial growth, Diagnostics, Imaging methods, Juvenile idiopathic arthritis, Oral health,
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Background
Juvenile idiopathic arthritis (JIA) is the most common
childhood rheumatic disease in Europe with an average
prevalence of 1 in 1000 children aged 0–15 years. JIA is
characterized by the persistent inflammation of at least
one joint that lasts for at least 6 weeks. The age at onset
of JIA is under 16 years of age [1]. The pathogenesis of
JIA is poorly understood, but interaction between envir-
onmental and genetic factors has been proposed. The
mean annual incidence rate of JIA in Estonia is 21.7 per
100 000 children aged 0–15 years (22.9 in girls and 19.3
in boys) [2].
The prevalence of clinically detectable temporoman-
dibular joint (TMJ) involvement in JIA varies between
38 and 72 %, depending on the diagnostic method used
and the JIA subtypes involved [2]. Because joint swelling
and other symptoms are seldom reported by patients,
TMJ has been described as “the forgotten joint” and
diagnostic imaging is considered mandatory to assess
JIA involvement [3]. Contrast-enhanced magnetic reson-
ance imaging (MRI) is considered the gold standard to
reliably diagnose both acute TMJ arthritis and deform-
ation of the TMJ and may have direct impact on treat-
ment decisions [4]. Biomarkers of diseases are valuable
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tools for correct diagnosis and for evaluating appropriate
treatment protocols. Genetic factors may play a role in
determining which individuals are more prone to de-
velop TMJ disorders or in predicting the severity of the
disease process. [5] If undetected, TMJ involvement can
lead to several functional disabilities, such as reduced
mandibular mobility and disorders of the mastication
muscles. Orthodontically, the TMJ arthritis may cause
significant limitations in sagittal and vertical mandibular
growth that can result in severe micrognathia and anter-
ior open bites with significant esthetic and functional re-
strictions [6]. Early diagnosis of TMJ disorders in JIA
patients can lessen individual’s future facial growth prob-
lems and dental arch discrepancies. It will also increase
the likelihood of treatment success for these patients [7].
It is equally important to monitor craniofacial function
and growth through post-diagnostic follow-up clinical
examinations. Since the etiology of TMJ pathology is
complex, future research faces the challenge of finding
methods to effectively differentiate between the etiolo-
gies behind JIA-related TMJ arthritis and other sub-
groups of temporomandibular disorders (TMD) induced
TMJ degeneration [8].
Management of TMJ complications in patients with
JIA is based on a combination of counseling, pharmaco-
logic therapies, physiotherapy, occlusal appliances, or-
thodontics, and surgery [9]. Despite the frequency with
which the TMJ is involved in patients with JIA, consen-
sus on treatment is lacking. Due to a poor understanding
of the etiology or pathogenesis of these diseases and the
lack of definitive diagnostic or therapeutic approaches,
patients often have to tolerate symptoms, including de-
bilitating pain, that substantially impact their quality of
life over extended periods of time [5].
An overview of JIA and its clinical manifestations
The International League of Associations for Rheumatol-
ogy (ILAR) has concluded that the term “juvenile idio-
pathic arthritis” describes seven subtypes of arthritis,
which are assessed according to an individual’s clinical
features during the first 6 months of disease: oligoarticu-
lar JIA, polyarticular JIA (both rheumatoid factor
positive and negative), systemic JIA, juvenile psoriatic
arthritis, enthesitis-related arthritis, and undifferentiated
arthritis [10]. JIA is generally more common in females,
although there are differences depending on the subset.
The most common JIA subtype is oligoarthritis, which
has two forms: persistent (affecting four joints or fewer)
and extended (affecting more than four joints) after the
first 6 months of the disease [11].
All joints can be affected by JIA, including the temporo-
mandibular. Characteristic joint manifestations of JIA are
chronic synovitis, swelling of the joint, arthralgia, and im-
paired joint mobility. Extra-articular manifestations of the
JIA include fever, rash (involvement of internal organs in
the case of the systemic subtype), chronic anterior uveitis,
and other [12].
Disease onset in smaller children is often abrupt, with
the child upon waking unable to walk due to swelling of
the joint(s) and morning stiffness a frequent complaint.
To alleviate the pain, the joint is held in the position of
maximum comfort.
When inflammation occurs within the synovial mem-
brane, an exudative phase occurs (cell infiltration and
granulation tissue formation) that leads to an increase in
the thickness of the synovial layer. These phases are in-
terrelated with an active phase of the disease, and subse-
quent immunopathological events perpetuate this initial
inflammatory reactions, which result in a chronic condi-
tion [13]. With joint tissue destruction, granulation tis-
sue forms and replaces the damaged tissue, forming a
pannus. The pannus infiltrates and erodes the articular
cartilage and adjacent bone, leading to condylar destruc-
tion. As for the TMJ, the condylar growth cartilage re-
sides beneath the superficial articular cartilage layer, so
the endochondral mandibular growth can be disturbed
when the condyle is being resorbed or eroded [14].
The uniqueness of the TMJ
The TMJ is different from other joints in the body. The
articular surface of TMJ is composed of fibrocartilage,
while in the other synovial joints, it is covered by hyaline
cartilage. Fibrocartilage is a better material than hyaline
cartilage for bearing the large amount of occlusal load
placed upon the TMJ [15]. Fibrocartilage is less suscep-
tible to the effects of aging and has a better ability to
repair. The cartilage of the mandibular condyle is a sec-
ondary cartilage compared to the primary articular car-
tilage found in all other joints. [16]. This secondary
cartilage contains both types of collagen—which may be
an adaptation to the complex biomechanical environ-
ment of the condylar cartilage—and also a chondroid
bone, which allows for highly diverse growth directions
and condylar and maxillofacial morphology [17].
Two developmental defects, Hunter-Thompson chondro-
dysplasia and fibroblast growth factor-receptor 3 (FGFR3)
achondroplasia, both of which afflict systemic load-bearing
joints but not the TMJ, provide further evidence of the
uniqueness of the TMJ [18]. TMJ demonstrates specific
organizational-anatomical and developmental differences
from all other joints.
From a functional point of view, the two joints—one
on each side of the head—are connected by the jawbone.
This means that the joints cannot move separately, with
one joint influencing the function of the other.
Another factor that makes the TMJ unique is that an
individual’s teeth position dictates its function. In order
to obtain maximal intercuspation of the teeth, TMJ is
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forced by the mastification muscles to move so that the
teeth fit together properly and this can lead to derange-
ment in the disc-condyle complex.
The articular disc is located between the two articular
surfaces of the TMJ. The disc divides the joint into two
sections, each with its own synovial membrane. Since
the disc is a separate structure and may move independ-
ently of the condyle, it can be displaced and cause many
problems. This disc-condyle complex derangement may
manifest itself in joint noises during jaw movement, pain
during functional movements, and limited mouth open-
ing and add further complexity for adequate diagnosis.
The mandibular condylar cartilage is the center of the
greatest growth in the craniofacial complex. The growth
center is located superficially, unlike in the other syn-
ovial joints [19]. The mandibular growth plate lies under
a thin layer of fibrocartilage located on the surface of the
condylar head [20].
Arthritis in the temporomandibular joint (TMJ) during
childhood and youth may affect condylar growth and is
considered the main reason for any altered facial structure
and changes in the dental occlusion of JIA patients [21].
Condylar growth impairment of the TMJ in JIA
The reason for this growth impairment is poorly under-
stood, there are several factors that might contribute to
this, such as the presence of high levels of proinflamma-
tory cytokines and chronic use of corticosteroids (CS) to
control JIA, malnutrition, and immobilization [22]. It
has been shown that direct destruction of the condylar
region has a high prevalence among patients with
JIA—erosive lesions in the condylar region caused by the
inflammation process [23]. Body’s growth hormone can
be altered by increased proinflammatory cytokines’ levels
and prolonged use of medical corticosteroids [13]. When
CS is used during the mandibular growth phase, a pre-
mature closing of the epiphyseal bone may occur [24].
These alterations seem to become more evident in pa-
tients aged 9–12 years. During this period is a growth
spurt which is accompanied by faster jaw growth [25].
With JIA, this growth disturbance has been associated
with a number of clinically significant outcomes, includ-
ing decreased chewing ability, malocclusion, and micro-
gnathia [26].
Craniofacial growth and dentoalveolar development in
JIA patients
The destructive changes in the mandibular condyle seem
to lead to a change in mandibular position, with a more
anterior position of the condyle in the glenoid fossa, and
to its reduced vertical growth. Both the condyle–fossa
positional change and reduced vertical condylar growth
lead to a posterior rotation of the mandible, mandibular
retrognathia, and malocclusion [27].
The condyle can grow until the third decade of life
[28], which is different from the suture of the maxilla
that is almost completed at 10 years of age [29]. If con-
dylar growth is inhibited, muscles of mastication force
the lower jaw to rotate backwards in relation to the cra-
nial base, giving a steeper mandibular plane angle and a
shorter posterior facial height. The result is a more convex
profile and reduced mandibular protrusion [30]. If only
one TMJ is affected by JIA, facial asymmetry occurs; as in
this case, only one area of mandibular growth is compro-
mised, while the other shows normal growth [13].
Posterior rotation of the mandible and the subsequent
decrease in mandibular dimensions in patients with JIA
can lead to an anterior open bite [31]. This open bite
can result in mastication overload of the posterior teeth,
muscles, and joint structures, which may cause muscle
imbalances and intracapsular disorders.
From an orthodontic perspective, JIA patients show a
significantly greater prevalence of anterior open bite, an
increased orthodontic treatment need according to the
morphological component of the Index of Orthodontic
Treatment Need (IOTN) and less normal bite than
healthy children [31]. They have a steeper occlusal plane,
tilting of the lower incisors, and a reduced height of the
ascending ramus [32].
Various JIA subtypes can impact orofacial structures
with different amount. The greatest alterations are no-
ticeable with the polyarticular subtype compared to
other JIA subtypes [27]. A mandibular growth disturb-
ance is also dependable on child’s age at disease onset.
Longer exposure to treatment or to the harmful effects
of the disease will increase the likelihood for interfered
development of the mandible. [33].
The teeth and gingiva can be indirectly affected by JIA
owing to physical limitations of the superior limbs of pa-
tients, which make performing adequate oral hygiene
difficult and contributes to a higher incidence of dental
and gingival problems among JIA patients when com-
pared to healthy children [25]. In a small study of 16 JIA
patients with a mean age of 9.3 years, the mean salivary
concentrations of calcium, phosphorus, potassium, lyso-
zyme, and IgA were significantly lower in the JIA pa-
tients when compared to healthy children [34].
Children with JIA also have a higher prevalence of
headaches, neck pain, and jaw dysfunction than non-JIA
controls, both at the time of TMJ disease diagnosis and
at the long-term follow-up [35].
The diagnosis of TMJ arthritis
A correct diagnosis is important to distinguish between
dental malocclusion and bone discrepancy, thus differen-
tiating the normal bone growth trajectory from an ab-
normal growth caused by a pathological condition [13].
Diagnosis of TMJ arthritis includes a questionnaire for
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history and epidemiological background, a pain anam-
nesis, and an examination that consists of an analysis of
the TMJ, the masticatory muscles, and the interaction of
TMJ function with the articular disc [8].
As the symptoms of TMJ arthritis may also mani-
fest in its surrounding structures, special care must
be paid to the whole orofacial complex during clinical
examination. Symptoms are more manifested during
mouth opening and chewing and are most commonly
noticeable in the TMJ area and the masseter muscle
region [8]. As with other joints, morning stiffness of
the TMJ is also a frequent complaint. TMJ symptoms
and a physical examination are not reliable methods
for the detection of TMJ arthritis. Many initially
asymptomatic cases during clinical examination are
later diagnosed to have TMJ damage by radiograhic
imaging methods [35]. Pain sensation among JIA pa-
tients varies considerably, but usually, pain is moder-
ate and fluctuates over time [36].
Like with other chronic diseases, TMJ arthritis-related
orofacial symptoms often fluctuate and can be difficult
to recall during the clinical examination. It is recom-
mendable to introduce a standardized patient question-
naire in which the patients report their orofacial
symptoms within the last 2–4 weeks [8].
Reduced mandibular range of motion and asymmetric
mouth opening are the two most common clinical signs
associated with TMJ involvement [37]. Maximal mouth-
opening capacity (MOC) increases linearly with age but
shows a wide range among children of the same age
group. Mean MOC (range) is 45 mm (25–69) for girls
and 45 mm (25–70) for boys [38]. A MOC of ≤29.5 mm
can be considered limited in children up to 3 years old;
a MOC of 34.5 mm and of 39.5 mm is limited for chil-
dren up to 6 years old and for those older than 7 years,
respectively [39]. Asymmetry in relation to the facial ver-
tical midline during opening of the mandibula may be a
consequence of the shortened condyle on the side of de-
viation but may also indicate an intercapsular disorder
on that side.
There are no standardized protocols to determine
intervals between routine clinical examinations for
JIA patients, and this should be adapted to each indi-
vidual patient regarding disease activity, age, com-
plaints, and detectable TMJ involvement. The current
age of the child and related future craniofacial growth
potential should also be a decisive factor in determin-
ing the interval. Disease onset before or during the
pubertal growth spurt can have a larger impact on
craniofacial development, and such patients should be
recalled more often [8].
There are no specific validated examination protocols
for patients with JIA. An expert-based classification and
diagnostic system was proposed in 2014 called
Diagnostic Criteria for TMD (DC/TMD) [40]. Being
regarded as a gold standard for TMD diagnosis, this cri-
terion consists of pain anamnesis, a questionnaire for a
case history, and a complex physical examination of
TMJ and masticatory muscles. It is considered a valid
screener and diagnostic criteria for detecting and differ-
entiating any pain-related TMDs [40]. Using this proto-
col for JIA patients is limited because it does not
evaluate granofacial growth or morphology [8]. A task
force within the EuroTMJoint research network is pre-
paring recommendations for a standardized clinical oro-
facial examination of patients with JIA, which are
expected to be published in 2016 on the webpage of the
euroTMJoint network [8].
Diagnostic imaging is considered mandatory when
assessing JIA involvement in TMJ [41]. Panoramic radi-
ography (OPTG) has the advantage of being available
and simple and is still used in many studies. Magnetic
resonance imaging (MRI) has become the new standard
for examining TMJ, as it allows noninvasive evaluation
of the joint.
With X-rays, the most commonly described feature of
TMJ is flattening of the condyle, which is usually a sign
of remodeling of the condyle [42]. The temporal bone
may also be involved in JIA, but it cannot be evaluated
using panoramic radiography. TMJ function is often
impaired in JIA patients. In children with JIA, maximal
condylar translation was less than one half of that
observed in the healthy controls, which was noticeable
even when JIA patients had normal mouth-opening
capacity [43].
There are some imaging findings that correlate to
clinical signs and symptoms, which may help with es-
tablishing an early diagnosis of TMJ arthritis. Clinical
assessment of limited mouth-opening capacity, man-
dibular deviation during mouth opening, and reduced
condylar translation is strongly associated with TMJ in-
volvement on imaging in a number of studies [43, 44].
Clinical predictors of TMJ involvement in studies using
conventional radiographic methods and MRI are young
age at onset (<4 years), long disease duration, systemic
or polyarticular disease subtype, and extended disease
course [26, 45, 46]. Many clinicians still use X-ray for
imaging during early phases of TMJ arthritis. However,
during early phases, OPTG has poor sensitivity, and it
appears to be better suited for studying TMJ bony
changes later in the disease course [45].
Panoramic examination is simple and accessible diag-
nostic method at most clinics and should be used as a
foundation to get an overview of the TMJ before more
sophisticated imaging methods are performed.
With the use of MRI, the condition of all joint compo-
nents can be assessed and inflammatory activity de-
tected. Long-standing TMJ involvement has been shown
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to cause bone deformation, frequently with secondary
osteoarthritis and quite often with mild contrast en-
hancement [42]. As shown in the subsequent MRI
examination, clinical symptoms were found to be poor
predictors of the presence or absence of TMJ involve-
ment in JIA patients [46, 47]. Active TMJ involvement
on MRI was associated with higher incidence of recent
involvement of other joints which signifies the need for
early diagnosis of TMJ involvement to help in directing
clinical management and obtain early intervention [48].
An early diagnosis of TMJ arthritis is essential to pre-
vent condylar destruction. At the time when clinical and
morphological signs like retrognathism or jaw asym-
metry become obvious, the condyles are already irrevers-
ibly damaged [49].
TMJ arthritis and TMJ involvement were significantly
associated with a younger age at onset of JIA [50]. Early
TMJ MRI led to changes in the treatment in 62 % of pa-
tients with 60 patients getting additional joint injections
and 9 patients getting systemic medication. Therefore, it
is recommended to perform TMJ MRI in young children
even if they require sedation, as they have an increased
rate of TMJ involvement which can stay undetected dur-
ing clinical examinations [4].
Ultrasound is routinely used to detect synovitis in
seve62 % of patients with 60 ral joints and has been
shown to be useful for monitoring the activity and
course of the disease process in children with JIA but
has low sensitivity compared to MRI [51].
The introduction of the conebeam computer tomog-
raphy (CBCT) system specifically designed for use in
dentistry provides a definite advantage over other tech-
niques due to its low radiation dose to the patient, lesser
cost for equipment, and ability to provide accurate 3D
images of the surface of the condyle. Diagnostic infor-
mation obtained is limited to the osseous joint compo-
nents and is not suitable for soft tissue evaluating soft
tissues [52].
CBCT imaging technology has been used for an
image-guided access to the superior joint space and for
arthroscopic examination and treatment of individuals
with disc perforations or adhesions [5].
The genetics of juvenile idiopathic arthritis
As with most complex diseases, such as JIA, different
genomic regions are suggested to contribute to the over-
all disease risk of JIA [53]. Genetic factors may play a
role in determining which individuals are more prone to
develop TMJ disorders or in predicting the severity of
the disease process [5]. Evidence for a genetic compo-
nent regarding the pathogenesis of JIA has come from
both twin and family studies: siblings of those affected
by JIA have a 15- to 30-fold increase in the prevalence
of JIA. A concordance rate of 25 % for JIA was found in
monozygotic twins [54]. JIA represents a clinically het-
erogeneous group of conditions, and given the relative
rarity of the disease, there are varied strategies associ-
ated with studies of the genetic background of JIA.
It has been suggested that several genetic factors are
shared with other autoimmune diseases, which are sup-
ported by the candidate gene studies [55].
Studies have shown that polymorphisms in the sero-
tonin transporter gene [56] and adrenergic receptor beta
gene 2 [57] cause an increase in the likelihood of
developing TMJ disorders. Also, polymorphism in the
estrogen receptor gene causes an increase in pain sus-
ceptibility in patients with TMJ osteoarthritis [58]. The
differences in findings between studies on the heritability
of TMJ disorders are likely resulted from the inclusion
of the many different subtypes of the diseases with some
having a greater genetic component while others have
minimal or no genetic basis [5].
In the last few years, genome-wide association studies
(GWAS) have been shown to be highly effective in dis-
covering new susceptibility loci for common complex
traits but have not contributed much in the field of JIA
research [59].
Strong evidence supports HLA class I and II alleles as
having an important role in the pathogenesis of different
subtypes of JIA [60]. Several studies have shown signifi-
cant correlations between the antigens associated with
early-onset oligoarticular, RF-negative polyarticular, and
RF-positive polyarticular JIA [60]. There are also a num-
ber of non-HLA genes that have been tested for the as-
sociation with JIA, most of them belonging to the
immunity-related genes [59]. The genetic background of
TMJ arthritis has not yet been specifically addressed.
Advances in understanding the genes that contribute or
predispose to TMJ disorders may make it possible to
identify patients who are at risk for developing TMJ dis-
orders and enable the implementation of strategies to
prevent the disease.
Biomarkers for juvenile idiopathic arthritis
Juvenile idiopathic arthritis consists of a heterogeneous
group of disorders. Clear distinctions between the vari-
ous subtypes are difficult because of unknown etiology
and complex genetic component. The use of reliable
biomarkers would be beneficial for diagnostic purposes
or for monitoring disease course. A biomarker is a
small component which is easily measurable in access-
ible patient material, e.g., blood, urine, or saliva, and is
ideally obtained using a relatively noninvasive ap-
proach [61]. Biomarkers may be helpful with predicting
disease type, course, or severity. They may also help to
predict response to medication and identify those chil-
dren who have obtained clinical remission [61]. Several
biomarkers are already in widespread use in routine
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care of JIA such as antinuclear antibody (ANA), C-
reactive protein (CRP), and rheumatoid factor (RF).
The presence of positive serum antinuclear antibody
(ANA) has been revealed in several studies to be asso-
ciated with an increased risk of chronic anterior uveitis
in JIA [62]. Two polyarticular forms of JIA are distin-
guished by the absence or presence of serum autoanti-
body, known as rheumatoid factor (RF). These two
clinical subgroups of JIA are distinct in their genetics,
age of onset, and prognosis [63]. In extended oligoar-
thritis, five or more joints are affected after the first
6 months; joint’s inflammation might be highly erosive
and may be treatment refractory. It has been shown
that compared to persistent oligoarticular JIA, CD4:CD8
ratio in synovial fluid is lower and the levels of the
chemokine CCL5 are higher in extended-to-be oli-
goarticular JIA [64].
The proinflammatory S100 proteins, S100A8/9 (also
known as calprotectin or myeloid-related protein (MRP)
8/14), and S100A12 have been described to be sensitive
markers for disease activity in JIA, and both correlate
well with physicians’ assessment of disease or with active
joint inflammation [65]. The level of S100 proteins in
serum may also show whether a patient will respond to
initial treatment with methotrexate [66]. In another
approach, evaluating gene expression profiles in children
with JIA before and after MTX showed three SNPs in
the SLC16A7 gene that may contribute to genetic vari-
ability in MTX response in [67].
Biomarkers could also be valuable to identifying pa-
tients at risk of disease relapse after discontinuation of
MTX treatment helping to detect a presence of subclin-
ical disease activity [61].
Many biomarkers are developed for the adult popula-
tion and are later applied to children.
However, some diseases only occur in children, and
the pathogenesis of disease is often different in children
compared with adults [65]. For example, MTX is a folate
antagonist and it is essential for numerous bodily func-
tions. Children are receiving higher absolute doses of
MTX for clinical efficacy which might be related to
serum folate concentration decrease with age.
Measurement of the polyglutamated form of the drug
in erythrocytes has been shown to correlate with im-
proved outcomes in adult rheumatoid arthritis patients
[68] but not in children with JIA [69]. The different anti-
folate effect of MTX might be related to changes in
folate concentration during growth.
Validated pediatric biomarkers are vital in caring for
JIA patient and should be objective of modern manage-
ment of arthritis. To obtain such goal, multi-center and
international collaborations are needed to support bio-
marker verification or validation in large multicenter
studies [61].
Treatment of JIA
The main objective of the treatment of JIA is to reduce
an individual’s pain and prevent or control joint damage
and loss of function [70]. JIA is a chronic disease that is
characterized by periods of remission and flare-up. Early
aggressive treatment is targeting longer or permanent
remission and is aimed at preventing body’s own im-
mune system to destroy joint’s tissues. Pharmacologic
management consists of nonsteroidal anti-inflammatory
drugs (NSAIDs), disease-modifying antirheumatic drugs
(DMARDs), biologic agents, and intra-articular and oral
steroids [71]. NSAIDs ease pain and reduce inflamma-
tion but do not prevent joint damage. Intra-articular
corticosteroids offer a very rapid relief of symptoms and
can spare the need for systemic therapy among patients
with persistent oligoarticular arthritis. Intra-articular
corticosteroids might be beneficial in cases where active
TMJ arthritis persists despite a use of systemic therapy,
and other joints remain in remission [72].
Methotrexate remains the most widely used conven-
tional DMARD in the management of JIA. It has long-
term beneficial effects in controlling disease activity, and
it reduces the exposure to other medications such as
prednisolone and NSAIDs. However, methotrexate can
be associated with a number of potentially serious
adverse effects, and therefore, its use requires careful
monitoring using blood tests and clinical supervision
from a medical specialist [73].
The development of biologics has changed the treat-
ment of JIA, with a variety of new drugs that target key
cytokines and other inflammatory mediators. They are co-
administered with methotrexate. Multiple categories of
biologics exist, targeting different key cytokines underlying
the inflammatory response with different disease subtypes.
Most common biologics are aimed at targeting tumor ne-
crosis factor (TNF), in case of systemic disease, interleukin
(IL)-1 and IL-6. There are also drugs that aim at T cell
blockade and B cell depletion [74]. Better understandig of
the etiopathogenesis of the subcategories of JIA makes it
easier to choose adequate treatment to the right child.
Current consensus is that most children with non-systemic
JIA respond well to TNFi and MTX and that most children
with sJIA respond well to IL-1 and IL-6 blockade [75].
Although the systemic treatment of JIA has improved
significantly, TMJ arthritis still can develop during the
course of the disease, even if patients are treated with
biologics [76].
The management of TMJ pathology in patients with
JIA is based on a combination of interventions, such as
counseling, pharmacologic therapies, physiotherapy,
occlusal appliances, orthodontics, and surgery [77]. The
main treatment goals for these patients are to improve
esthetics and function, reduce pain, and avoid progres-
sion of the process.
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It is advisable to educate the patient about the possi-
bilities for reducing the load put on the joint. Patient
education should begin by informing the patient that the
teeth should only be in contact during chewing, speak-
ing, and swallowing. At all other times, the jaw should
be positioned with the teeth apart. If the patient has an
intracapsular disorder, it may be advisable to chew with
the same side, because this increases interarticular pres-
sure in the contralateral joint and decreases intra-
articular pressure in the ipsilateral joint [78]. Warm heat
may be helpful with chronic pain. Any activities that
increase pain should be resisted.
Patients who experience TMD symptoms often de-
crease the use of their jaw because of pain. If disuse is
prolonged, the muscles can become shortened and atro-
phied. The patient should therefore be instructed in self-
administering exercises that largely fall into four types:
passive muscle stretching, assisted muscle stretching,
resistance exercises, and postural training [79]. These
exercises are repeated ten times, six sessions a day. If
any of them elicit pain, they are discontinued. The main
objective of these exercises is to help restore normal
function and range of movement.
When nocturnal clenching or bruxism is suspected or
there exists an occlusal instability, the use of a stabilization
appliance is indicated to decrease muscle hyperactivity
and correct any occlusal discrepancies. Because the eti-
ology of temporomandibular symptoms are often com-
plex, it is advisable that any initial therapy should
generally be reversible and noninvasive. When an appli-
ance helps to modify an etiologic factor, it might also be
considered as a diagnostic tool.
The most common type of appliance is a stabilization
appliance. It provides an occlusal relationship considered
optimal for the patient. When it is in place, the condyles
are in their most musculoskeletally stable position at the
time the teeth are contacting evenly and simultaneously.
Canine disocclusion of the posterior teeth during eccen-
tric movement is also provided. The treatment goal of
the stabilization appliance is to eliminate any orthopedic
instability between the occlusal position and the joint
position, thus removing this instability as a causative
factor of TMD [78].
There is evidence that intra-articular corticosteroid
therapy (IACS) is effective in many patients with TMJ
arthritis, and although its short-term safety profile has
been well established, there remain concerns about long-
term effects on mandibular growth [80].
Orthodontic treatment is carried out during the remis-
sion phase of JIA and follows the protocol for non-JIA
children. Early treatment should be aimed at supporting
the symmetric growth, avoiding compensations, and
providing space for the normal development of the
dentoalveolar area [81].
Avoidance of mandibular and craniofacial growth dis-
turbances is a primary aim in TMJ arthritis management
in children since the magnitude of the treatment involves
substantial and clinically challenging orthopedic and pos-
sibly surgical interventions that proceed over a long
period which requires excellent patient cooperation [82].
Conclusions
The etiological factors of JIA are largely unknown. Early
and correct TMD diagnosis in patients with JIA is im-
portant in order to treat and prevent a negative effect of
the chronic inflammatory disease process primarily on
the TMJs and secondarily on craniofacial development.
Etiology and pathogenesis of JIA is poorly understood
and lack of person tailored therapeutic approaches
impact patients’ quality of life through their lives. The
screening for TMJ arthritis, description of possible den-
tofacial growth disturbances and malocclusions, and reg-
istering the Index of Orthodontic Treatment Need
should be beneficial to outline a long-term treatment
plan for JIA patients. Magnetic resonance imaging is the
most recommendable examination method but requires
sedation in young children. The introduction of the con-
ebeam computer tomography has opened up new oppor-
tunities for deriving additional diagnostic information; it
is a noninvasive and repeatable tool for individualization
of treatment. Future classification of JIA might be revis-
ited when clinical and laboratory features are accompan-
ied by better understanding of genetic predispositions
for gene expression and cytokine profiles. Genetic analysis,
novel biomarkers, and imaging methods will improve the
specificity of diagnostic and therapeutic approaches for
diseases of the TMJ [5].
Multi-center and international collaborations are needed
to gain insights into how genetics and environment are in-
tervened in the onset and disease course of JIA and in
their role leading to the development of TMJ arthritis.
To achieve these targets, propagation of multidisciplin-
ary expertise in dentistry and networking of scientific and
dental/medical centers is mandatory, in order to shift the
paradigm from reactive medical services to predictive, pre-
ventive, and personalized medicine in dentistry [45].
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